Doctors Revision

Endocrine & Metabolic System

Central Precocious Puberty (CPP)

Onset of pubertal changes (secondary sexual characteristics, accelerated growth, bone maturation) before the normal age (before 8 years in girls, before 9 years in boys), caused by premature activation of the hypothalamic-pituitary-gonadal (HPG) axis.

Also known as: Gonadotropin-Dependent Precocious Puberty, Early Puberty

Open in the interactive guide
On this page

Referral and warning signs

When to refer

Refer ALL children with signs of precocious puberty (before age 8 in girls, 9 in boys) to a Paediatric Endocrinologist/Specialist for: Diagnosis confirmation (GnRH stim test, MRI). Identification of underlying cause. Initiation and management of GnRH agonist therapy.

Red flags

  • Onset of puberty before age 8 (girls) / 9 (boys)
  • Rapidly progressing pubertal signs
  • Accelerated growth velocity
  • Neurological symptoms (headache, visual changes, seizures)
  • Signs suggesting peripheral precocity (e.g., virilization without testicular enlargement in boy, isolated breast development with vaginal bleeding in girl)

Signs and symptoms

  • Girls (<8 years): Premature breast development (thelarche), Pubic/axillary hair growth (pubarche/adrenarche), Onset of menstruation (menarche), Accelerated growth velocity, Advanced bone age.
  • Boys (<9 years): Testicular enlargement (>4ml volume or >2.5cm length), Penile enlargement, Pubic/axillary/facial hair growth, Deepening voice, Acne, Accelerated growth velocity, Advanced bone age.
  • Sequence of pubertal events is typically normal, just occurs early.

Risk factors

  • Idiopathic (most common cause, especially in girls).
  • CNS abnormalities (Secondary CPP):
  • - Brain tumours (hypothalamic hamartoma, glioma, astrocytoma).
  • - CNS infections (meningitis, encephalitis).
  • - Brain malformations (hydrocephalus, arachnoid cysts).
  • - Cranial irradiation.
  • - Head trauma.
  • Previous exposure to exogenous sex steroids.
  • Genetic factors (rare familial cases).

Diagnosis

Clinical assessment

Diagnosis based on appearance of secondary sexual characteristics before age 8 (girls) or 9 (boys). Assess tempo of puberty, growth velocity. Detailed history (onset, sequence, CNS symptoms, exposures). Physical exam (Tanner staging, height/weight, neurological exam). Differentiate from benign variants (premature thelarche, premature adrenarche) and gonadotropin-independent precocious puberty (peripheral causes).

Investigations

  • Bone Age Assessment (X-ray of left hand/wrist): Typically advanced compared to chronological age.
  • Baseline Gonadotropin levels (LH, FSH): May be in pubertal range, but often low/prepubertal basally.
  • GnRH Stimulation Test: Confirmatory test for CPP. Measures LH/FSH response after GnRH agonist administration. A pubertal LH response confirms central activation of HPG axis (specialist test).
  • Sex Steroid levels (Estradiol in girls, Testosterone in boys): May be elevated into pubertal range.
  • Pelvic Ultrasound (Girls): Assess ovarian/uterine size and morphology (pubertal changes).
  • Brain MRI: Essential to rule out CNS lesions (tumours, malformations) as the cause, especially in boys and very young girls (<6 years).
  • Genetic testing (rare familial cases).

Diagnostic criteria

Clinical signs of puberty before age 8 (girls) / 9 (boys) + Advanced bone age + Confirmed pubertal response on GnRH stimulation test.

Management

Non-pharmacological management

  • Treat Underlying CNS Cause (if identified): e.g., surgery/radiation for tumour.
  • Psychosocial Support: For child and family to address emotional/social challenges of early puberty.
  • Monitor growth and pubertal development.

Pharmacological treatment

  • Goal: Suppress puberty to allow for further growth (preserve adult height potential) and align psychosocial development.
  • GnRH Agonist Therapy: Treatment of choice. Suppresses pituitary gonadotropin release, halting pubertal progression and slowing bone age advancement.
  • - Leuprolide acetate depot suspension: Administered IM monthly (e.g., 7.5mg) or every 3 months.
  • - Histrelin implant: Long-acting subdermal implant (annual).
  • - Treatment typically continued until a more appropriate age for puberty (e.g., 11-12 years).
  • - Requires specialist initiation and monitoring.

Monitoring

Monitor growth velocity, pubertal stage (Tanner), bone age progression (e.g., every 6-12 months). Monitor LH/FSH/sex steroid levels to confirm suppression on GnRH agonist therapy. Monitor for side effects of treatment (local reactions, rare headaches).

Complications

  • Short adult stature (due to premature fusion of growth plates).
  • Psychosocial difficulties (feeling different from peers, potential for early sexualisation/risk behaviours).
  • Emotional distress.
  • Complications related to underlying CNS lesion if present.

Prevention

  • Not generally preventable, but early detection and treatment of CNS lesions can address secondary CPP.

Patient education

  • (To parents/child) Explain CPP and its cause (if known).
  • Rationale for treatment (preserve height, psychosocial adjustment).
  • How GnRH agonist therapy works (suppresses puberty temporarily).
  • Administration schedule (injections/implant).
  • Need for regular monitoring.
  • Expected outcomes and when treatment might stop.
  • Addressing psychosocial concerns.

Uganda-specific notes

Recognition may be delayed. Access to specialist Paediatric Endocrine care, hormonal testing (esp. GnRH stimulation), Brain MRI, and GnRH agonist therapy is extremely limited.

References

  • Uganda Clinical Guidelines (UCG) 2023

    Chapter 8, Section 8.1.8

Scroll to Top